These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

659 related articles for article (PubMed ID: 10807385)

  • 1. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
    Boyd J; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Maresco DL; Saigo PE; Almadrones LA; Barakat RR; Brown CL; Chi DS; Curtin JP; Poynor EA; Hoskins WJ
    JAMA; 2000 May; 283(17):2260-5. PubMed ID: 10807385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival in women with BRCA-associated ovarian carcinoma.
    Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
    Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations.
    Zweemer RP; Shaw PA; Verheijen RM; Ryan A; Berchuck A; Ponder BA; Risch H; McLaughlin JR; Narod SA; Menko FH; Kenemans P; Jacobs IJ
    J Clin Pathol; 1999 May; 52(5):372-5. PubMed ID: 10560359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
    Lacour RA; Westin SN; Meyer LA; Wingo SN; Schorge JO; Brooks R; Mutch D; Molina A; Sutphen R; Barnes M; Elder J; Teoh D; Powell CB; Choubey V; Blank S; Macdonald HR; Brady MF; Urbauer DL; Bodurka D; Gershenson DM; Lu KH
    Gynecol Oncol; 2011 May; 121(2):358-63. PubMed ID: 21276604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
    Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
    J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
    Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
    J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hereditary ovarian cancer.
    Prat J; Ribé A; Gallardo A
    Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
    Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
    Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
    Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
    Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer.
    Levine DA; Federici MG; Reuter VE; Boyd J
    Gynecol Oncol; 2002 Jun; 85(3):431-4. PubMed ID: 12051869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
    Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
    Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
    Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
    JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.